AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04795531
Drug: Placebo insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Trial: NCT04795531
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Trial: NCT04795531
Drug: Placebo insulin degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Trial: NCT05544721
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
Trial: NCT05193565
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Orally, once-daily in the morning - Check the blood concentration of Sirolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8ng/mL
Trial: NCT05193565
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Up to 1g BID(total 2g daily), PO
Trial: NCT04704622
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
Trial: NCT04704622
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam intranasal injection,0.2mg/kg, once, 30 min preoperative
Trial: NCT04704622
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
Trial: NCT06520007
Drug: Doxycyclin
RxNorm normalized name: Doxycyclin
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.
Trial: NCT00172341
Drug: Staloral TM
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05604742
Drug: Belimumab (Benlysta)
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
Trial: NCT04220008
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04220008
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT04220008
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04220008
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04220008
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04220008
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05325528
Drug: Tislelizumab in Combination with Oxaliplatin and Tegafur
RxNorm normalized name: Tislelizumab
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 cycles of Tislelizumab plus SOX regimen every 21 days
Trial: NCT05176158
Drug: Dexketoprofen 25 MG
RxNorm normalized name: dexketoprofen 25 MG
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill at morning
Trial: NCT06490328
Drug: DKF-MA102
RxNorm normalized name: DKFZ-PSMA-11 Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered twice at 12-week intervals
Trial: NCT05176158
Drug: Dexketoprofen 25 MG
RxNorm normalized name: dexketoprofen 25 MG
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill at night
Trial: NCT00002366
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05298332
Drug: ATI-2173 50 mg
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-2173 is a phosphoramidate prodrug of the oral, non-chain terminating nucleoside analog clevudine being developed by Antios Therapeutics, Inc. for treatment of men and women with chronic hepatitis B (CHB)
Trial: NCT06104358
Drug: HU6
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HU6 is being evaluated for its effect on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function
Trial: NCT06697197
Drug: BMS-986482
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06547736
Drug: SHR-A1904 or/and HRS-4642
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.
Trial: NCT06697197
Drug: Nivolumab and rHuPH20
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06697197
Drug: Nivolumab/relatlimab/rHuPH20
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06697197
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06698003
Drug: Mogamulizumab
RxNorm normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses
Trial: NCT05134649
Drug: OnabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intramuscular Injection
Trial: NCT06519565
Drug: PRG-1801
RxNorm normalized name: PRG-A01
DrugBank: PRG-A01 (DB18613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRG-1801 is a chimeric antigen receptor T-cell (CAR-T) therapy targeting BCMA. Participants will undergo leukapheresis to collect mononuclear cells for PRG-1801 manufacturing. Prior to infusion, patients receive lymphodepletion with cyclophosphamide (250-300 mg/m2/day) and fludarabine (25-30 mg/m2/day) for 3 days. PRG-1801 is then administered as a single intravenous infusion at one of three dose levels: 35×10\^6, 100×10\^6, or 300×10\^6 CAR-T cells. Premedication with antipyretics and antihistamines is given 30-60 minutes before infusion. The infusion rate is 2-5 ml/min. Patients are monitored for safety and efficacy for up to 24 months post-infusion. Some patients may be eligible for a second infusion if they respond initially but later relapse.
Trial: NCT05063201
Drug: Cariprazine 1.5 MG
RxNorm normalized name: cariprazine 1.5 MG
DrugBank: Cariprazine (DB06016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will attend two visits per week during the 8-week Outpatient Treatment Phase. Counseling services, in the form of Medication Management (MM) will be provided weekly. A urine sample for drug testing, vitals, AEs, and COWS will be collected/assessed at each visit. At the first weekly visit attended, concomitant medications, medication compliance, AIMS and a blood sample for later analysis of plasma levels of cariprazine and its metabolites will also be collected. The TLFB, C-SSRS, CSSA, SOWS, BSCS, DTS and a UPT (females only) will be collected once weekly. On the final appointment of week 8 only, a physical exam and ECG will be performed and standard laboratory measures (blood chemistry, CBC with differential, fasting glucose and lipids, serum prolactin, medical urinalysis) will be assessed. During week 8, additional assessments will be collected, including the ASI, HAM A/D and Treatment Opinion Form (TOF).
Trial: NCT06011083
Drug: Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: using topical ointment containing calcipotriol and betamethasone dipropionate for plaque psoriasis.
Trial: NCT05472792
Drug: tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.
Trial: NCT05730842
Drug: EDG-5506 Tablet
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Oral Dose - Tablet
Trial: NCT05730842
Drug: Radiolabeled EDG-5506 Suspension
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Oral Dose
Trial: NCT05730842
Drug: Radiolabeled EDG-5506 Intravenous
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Intravenous Dose
Trial: NCT06084364
Drug: Injection of triamcinolone acetonide into the CMC-1 joint
RxNorm normalized name: triamcinolone acetonide Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraarticular injection with triamcinolone acetonide
Trial: NCT04883138
Drug: GIGA-2050
RxNorm normalized name: Hippoglossus gigas flesh
DrugBank: Atlantic halibut (DB15549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Hyperimmune Polyclonal Antibody
Trial: NCT05448456
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gram of tranexamic acid in 100 ml of 0.9% normal saline
Trial: NCT05511779
Drug: Brincidofovir
RxNorm normalized name: Brincidofovir
DrugBank: Brincidofovir (DB12151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCV 0.3 mg/kg BIW or 0.4 mg/kg BIW administered as a continuous IV infusion over 2 hours
Trial: NCT05019209
Drug: House Dust Mite Allergen
RxNorm normalized name: house dust mite allergen extract
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D. pteronyssinus lyophilisate dissolved in 5% sodium chloride solution, spray dried
Trial: NCT06014762
Drug: Rimiducid
RxNorm normalized name: Rimiducid
DrugBank: Rimiducid (DB04974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single weight-based IV administration
Trial: NCT05009901
Drug: Alpha Lipoic Acid 600 MG Oral Tablet
RxNorm normalized name: alpha lipoic acid 600 mg ORAL TABLET
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha lipoic acid 600 mg daily for 8 weeks
Trial: NCT05600075
Drug: microneedling with topical glycolic acid 35%.
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 patients will be subjected to microneedling with topical glycolic acid 35%. Selected patients will receive one session of microneedling combined with a topical agent, with two weeks interval till complete clearance or up to 6 sessions.
Trial: NCT05226546
Drug: Platelet rich plasma (PRP)
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
Trial: NCT05542264
Drug: SEP-363856
RxNorm normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP-363856 will be supplied as over-encapsulated tablets. Multiple tablets may be required to achieve a single dose.
Trial: NCT05542264
Drug: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
RxNorm normalized name: Priorix
DrugBank: Measles virus vaccine live attenuated (DB10315)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA will be prepared by the pharmacy staff according to the patient's prescribed treatment and will be orally administered. Multiple tablets or capsules may be required to achieve a single dose.
Trial: NCT05756322
Drug: LBS-007
RxNorm normalized name: spinosad
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open Label.
Trial: NCT05036135
Drug: AV-101
RxNorm normalized name: AV-101
DrugBank: AV-101 (DB12878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV-101 (imatinib) administered via dry powder inhalation
Trial: NCT05646082
Drug: Dostarlimab in Combination Antiretroviral Therapy
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive dostarlimab at the fixed dose of 500 mg dose Q3W for the first 4 doses followed by a fixed 1000 mg dose Q6W until week 48 of treatment.
Trial: NCT05221892
Drug: Ginger
RxNorm normalized name: Ginger
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets to be taken 30 minutes before each of 4 trips.
Trial: NCT06214403
Drug: MET-2
RxNorm normalized name: Met
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microbial Ecosystem Therapeutics (MET) is a defined microbial community derived from healthy donor stool. MET capsules are orally administered mixtures of pure cultures of human-derived bacterial strains.
Trial: NCT06501924
Drug: Topical minoxidil 5%
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 5%
Trial: NCT06501924
Drug: DA-002
RxNorm normalized name: CENPLACEL-L COMPONENT OF PDA-002
DrugBank: Cenplacel-L (DB19188)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Alpha 1 Agonist (GRAS)
Trial: NCT06325956
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Take metformin for six months.
Trial: NCT06586281
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a longitudinal study consisting of a two-time visit by psoriatic arthritis patients. The aim of the study is to determine the effect of biological therapies in liver disorders in patients with psoriatic arthritis.
Trial: NCT05068349
Drug: Butylphthalide
RxNorm normalized name: BUTYLPHTHALIDE
DrugBank: Butylphthalide (DB12749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
Trial: NCT05506254
Drug: hLB-001
RxNorm normalized name: SUCROSE DISTEARATE (HLB 5)
DrugBank: LB-001 (DB17685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hLB-001 gene therapy
Trial: NCT04778592
Drug: ETX-018810
RxNorm normalized name: Polygonatum biflorum root etxract
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT04734457
Drug: Levothyroxin
RxNorm normalized name: Levothyroxin
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We assess the effect of early diagnosis of CH by neonatal screening and start of treatment on the final height of the patients
Trial: NCT06110403
Drug: TRIXEO AEROSPHERE
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days.
Trial: NCT05718258
Drug: Venglustat (GZ402671)
RxNorm normalized name: Venglustat
DrugBank: Venglustat (DB14966)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT06701305
Drug: Efinopegdutide
RxNorm normalized name: Efinopegdutide
DrugBank: Efinopegdutide (DB15077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injectable solution
Trial: NCT05469919
Drug: Ceralasertib
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralasertib taken orally
Trial: NCT06464770
Drug: Chlorhexidine Gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at lower pressure (similar to a gentle wipe) for 30 seconds Control Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at higher pressure (similar to a massage) for 30 seconds
Trial: NCT06480201
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine infusion amount is dictated by BMI, sex, and age.
Trial: NCT05525910
Drug: Nirmatrelvir/ ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
Trial: NCT05525910
Drug: Nirmatrelvir/ritonavir
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition
Trial: NCT06521216
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all patients will receive 200 mg elemental iron (ferrous sulphate)
Trial: NCT05357040
Drug: Nitrous oxide gas for inhalation
RxNorm normalized name: nitrous oxide Gas for Inhalation
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60-minute sessions of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) or 25% nitrous oxide in oxygen (FiO2 0.75), administered weekly for 4-weeks.~Administration will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Trial: NCT05162586
Drug: Enpatoran low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive film-coated tablets of Enpatoran at a low dose orally, twice daily (BID) up to 24 weeks.
Trial: NCT05162586
Drug: Enpatoran medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive film-coated tablets of Enpatoran at a medium dose, orally, BID up to 24 weeks.
Trial: NCT05162586
Drug: Enpatoran high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Enpatoran (DB16501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive film-coated tablets of Enpatoran at a high dose, orally, BID up to 24 weeks.
Trial: NCT05895994
Drug: RD13-02 cell infusion
RxNorm normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.02 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NADA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML / Neisseria meningitidis serogroup C oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup W-135 oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML / Neisseria meningitidis serogroup Y oligosaccharide diphtheria CRM197 protein conjugate vaccine 0.01 MG/ML [Penmenvy]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAR-T cells
Trial: NCT00002433
Drug: Interferon gamma-1b
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05894421
Drug: TQB2223 injection+ Penpulimab Injection
RxNorm normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.
Trial: NCT06398873
Drug: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300mg/2 weeks
Trial: NCT04749914
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT04749914
Drug: Dabigatran Etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.